The stock of MaxCyte Inc (MXCT) has gone down by -13.25% for the week, with a -29.57% drop in the past month and a -14.70% drop in the past quarter. The volatility ratio for the week is 5.59%, and the volatility levels for the past 30 days are 5.61% for MXCT. The simple moving average for the past 20 days is -16.21% for MXCT’s stock, with a -25.24% simple moving average for the past 200 days.
Is It Worth Investing in MaxCyte Inc (NASDAQ: MXCT) Right Now?
Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MXCT is 97.35M and currently, short sellers hold a 2.78% of that float. On March 12, 2025, MXCT’s average trading volume was 553.28K shares.
MXCT) stock’s latest price update
The stock of MaxCyte Inc (NASDAQ: MXCT) has decreased by -11.50 when compared to last closing price of 3.47.Despite this, the company has seen a loss of -13.25% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-11 that Start Time: 16:30 January 1, 0000 5:12 PM ET MaxCyte, Inc. (NASDAQ:MXCT ) Q4 2024 Earnings Conference Call March 11, 2025, 16:30 PM ET Company Participants Maher Masoud – President and CEO Doug Swirsky – CFO Erik Abdo – IR Conference Call Participants Matt Larew – William Blair Julie Simmonds – Panmure Liberum Brendan Smith – TD Cowen Mark Massaro – BTIG Matt Hewitt – Craig-Hallum Operator Thank you for standing by and welcome to MaxCyte’s Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
Analysts’ Opinion of MXCT
Many brokerage firms have already submitted their reports for MXCT stocks, with Craig Hallum repeating the rating for MXCT by listing it as a “Buy.” The predicted price for MXCT in the upcoming period, according to Craig Hallum is $7 based on the research report published on November 29, 2023 of the previous year 2023.
MXCT Trading at -26.64% from the 50-Day Moving Average
After a stumble in the market that brought MXCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.62% of loss for the given period.
Volatility was left at 5.61%, however, over the last 30 days, the volatility rate increased by 5.59%, as shares sank -29.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.26% lower at present.
During the last 5 trading sessions, MXCT fell by -17.51%, which changed the moving average for the period of 200-days by -36.52% in comparison to the 20-day moving average, which settled at $3.66. In addition, MaxCyte Inc saw -26.18% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MXCT starting from Johnston John Joseph, who sale 3,000 shares at the price of $4.64 back on Jan 27 ’25. After this action, Johnston John Joseph now owns 141,950 shares of MaxCyte Inc, valued at $13,935 using the latest closing price.
Sandoval David I., the GENERAL COUNSEL of MaxCyte Inc, sale 4,466 shares at $4.54 during a trade that took place back on Jan 13 ’25, which means that Sandoval David I. is holding 41,447 shares at $20,272 based on the most recent closing price.
Stock Fundamentals for MXCT
Current profitability levels for the company are sitting at:
- -1.3 for the present operating margin
- 0.76 for the gross margin
The net margin for MaxCyte Inc stands at -1.06. The total capital return value is set at -0.22. Equity return is now at value -16.00, with -13.87 for asset returns.
Based on MaxCyte Inc (MXCT), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -1.04.
Currently, EBITDA for the company is -42.91 million with net debt to EBITDA at 0.21. When we switch over and look at the enterprise to sales, we see a ratio of 8.07. The receivables turnover for the company is 8.25for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.81.
Conclusion
To wrap up, the performance of MaxCyte Inc (MXCT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
